Plasmid DNA Manufacturing Market is Estimated to Witness High Growth Owing to Technological Advancements in DNA Synthesis
Plasmid DNA is circular DNA molecules that can replicate independently of the chromosomal DNA within a cell. Plasmid DNA is employed extensively in research, bioproduction, and gene and cell therapies. Plasmid DNA manufacturing involves steps like cloning, amplification, purification, and analyzing the quality of plasmid DNA. Advances in DNA synthesis such as Gibson assembly, droplet microfluidics, and next-generation gene editing tools have enabled rapid engineering and manufacturing of custom plasmids. The rising number of gene and cell therapy clinical trials have created substantial demand for GMP-grade plasmid DNA.
The Global Plasmid DNA Manufacturing Market is estimated to be valued at US$ 1038.19 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Plasmid DNA Manufacturing are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing. Key opportunities in the market include the rising demand for plasmid vectors from biopharmaceutical companies and CMOs for gene and cell therapy development and production. Advancements like Gibson assembly and microfluidics are enabling rapid, scalable plasmid engineering and manufacturing.
Market Drivers
The Plasmid DNA Manufacturing Market Trends of gene and cell therapy clinical trials, rising demand for plasmid vectors for vaccine development against COVID-19 and other diseases, and focus on genome editing and DNA synthesis technologies for developing novel therapeutics. The focus of biopharma companies and researchers on DNA vaccines and gene therapies to treat cancers, genetic disorders, and infectious diseases is expected to significantly drive the demand for plasmid DNA over the forecast period.
Challenges in the plasmid DNA manufacturing market
Get More Insights On, Plasmid DNA Manufacturing Market
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian